Case Report: Durable complete response of metastatic hepatocellular carcinoma with asymptomatic hyperamylasemia to combined immunotherapy of anti-cytotoxic T lymphocyte-associated antigen 4 plus anti-programmed cell death-1 antibodies.
CTLA-4 inhibitor
PD-1 inhibitor
asymptomatic hyperamylasemia
combined immunotherapy
hepatocellular carcinoma
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
08
2023
accepted:
26
09
2023
medline:
1
11
2023
pubmed:
23
10
2023
entrez:
23
10
2023
Statut:
epublish
Résumé
Combined immunotherapy has shown promising results in the treatment of advanced HCC, whereas the priority population that would respond to the combined immunotherapy is still elusive. In addition, HCC with asymptomatic hyperamylasemia was not reported previously. An aged patient was diagnosed as HCC with BCLC stage C (bone metastasis). Notably, this patient showed asymptomatic hyperamylasemia. The patient was then enrolled in a trial evaluating combined immunotherapy of anti-PD-1 antibody sintilimab (IBI308) plus anti-CTLA-4 antibody (IBI310) in advanced HCC. After being treated with combined immunotherapy, this patient rapidly achieved complete response (CR) according to mRECIST criteria or immune partial response (iPR) according to iRECIST criteria and maintain the CR state for more than 12 months. Interestingly, serum levels of amylase and lipase in this patient were reduced after treatment. We reported, for the first time, a case of metastatic HCC with asymptomatic hyperamylasemia, and suggested that HCC patients with asymptomatic hyperamylasemia may benefit from combined immunotherapy of anti-CTLA-4 and PD-1 antibodies.
Sections du résumé
Background
Combined immunotherapy has shown promising results in the treatment of advanced HCC, whereas the priority population that would respond to the combined immunotherapy is still elusive. In addition, HCC with asymptomatic hyperamylasemia was not reported previously.
Case presentation
An aged patient was diagnosed as HCC with BCLC stage C (bone metastasis). Notably, this patient showed asymptomatic hyperamylasemia. The patient was then enrolled in a trial evaluating combined immunotherapy of anti-PD-1 antibody sintilimab (IBI308) plus anti-CTLA-4 antibody (IBI310) in advanced HCC. After being treated with combined immunotherapy, this patient rapidly achieved complete response (CR) according to mRECIST criteria or immune partial response (iPR) according to iRECIST criteria and maintain the CR state for more than 12 months. Interestingly, serum levels of amylase and lipase in this patient were reduced after treatment.
Conclusion
We reported, for the first time, a case of metastatic HCC with asymptomatic hyperamylasemia, and suggested that HCC patients with asymptomatic hyperamylasemia may benefit from combined immunotherapy of anti-CTLA-4 and PD-1 antibodies.
Identifiants
pubmed: 37869012
doi: 10.3389/fimmu.2023.1274449
pmc: PMC10587582
doi:
Substances chimiques
Antibodies, Monoclonal
0
Abatacept
7D0YB67S97
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1274449Informations de copyright
Copyright © 2023 Gao, Chang, Chen, Zhang, Zhang, Luo and Ding.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Adv Med Sci. 2010;55(2):143-5
pubmed: 21109499
J Natl Cancer Inst. 2021 Nov 29;113(12):1648-1669
pubmed: 34240195
JAMA Oncol. 2020 Nov 01;6(11):e204564
pubmed: 33001135
Int J Gynecol Cancer. 2004 Mar-Apr;14(2):378-80
pubmed: 15086742
Indian J Pediatr. 2016 Jan;83(1):81-2
pubmed: 25893529
Am Surg. 2014 Feb;80(2):191-6
pubmed: 24480222
Clin Chim Acta. 2001 Jul 5;309(1):73-83
pubmed: 11408008
J Cancer Res Clin Oncol. 1994;120(4):213-20
pubmed: 7507116
Ann Clin Biochem. 2014 Jan;51(Pt 1):5-7
pubmed: 24194585
Ann Clin Biochem. 2014 Jan;51(Pt 1):101-5
pubmed: 24048720